Search - tctmd.com

Displaying 401 - 420 of 585

Sort: Relevancy | Date

Triple Therapy Not Being Widely Used in A-fib Patients Undergoing PCI

News Daily News

Triple Therapy Not Being Widely Used in A-fib Patients Undergoing PCI

May 23, 2017

Best Antiplatelet Therapy in Real-World PCI? European Registries Fuel the Debate

News Conference News EuroPCR 2017

Best Antiplatelet Therapy in Real-World PCI? European Registries Fuel the Debate

May 22, 2017

No Very Late Scaffold Thrombosis Risk With Absorb BVS in China, Japan

News Conference News EuroPCR 2017

No Very Late Scaffold Thrombosis Risk With Absorb BVS Studies in China, Japan

Michael O'Riordan

May 17, 2017

DESSOLVE III: MiStent Holds Up Well Against Xience at 12 Months, Hints at Potential Longer-Term Benefit

News Conference News EuroPCR 2017

DESSOLVE III: MiStent Holds Up Well Against Xience at 12 Months, Hints at Potential Longer-Term Benefit

Michael O'Riordan

May 16, 2017

TOPIC: Replacing P2Y12 Inhibitors With Clopidogrel 1 Month After ACS Saves Money, Prevents Bleeding

News Conference News EuroPCR 2017

TOPIC: Replacing P2Y12 Inhibitors With Clopidogrel 1 Month After PCI Saves Money, Prevents Bleeding in ACS

Yael L. Maxwell

May 16, 2017

More Excess Bleeding and No Benefit With Triple Therapy After PCI, Meta-analysis Finds

News Daily News

More Excess Bleeding and No Benefit With Triple Therapy After PCI, Meta-analysis Finds

May 05, 2017

Extended DAPT May Benefit Patients With CAD and PAD, but With Caveats

News Daily News

Extended DAPT May Benefit Patients With CAD and PAD, but With Caveats

May 03, 2017

‘Forgotten’ Patients With Mechanical Heart Valves Undergoing PCI Pose Clinical Conundrum

News Daily News

‘Forgotten’ Patients With Mechanical Heart Valves Undergoing PCI Pose Clinical Conundrum

April 27, 2017

Long-term MI Risk Among Stable CAD Patients: Some Clues From CORONOR

News Daily News

Long-term MI Risk Among Stable CAD Patients: Some Clues From CORONOR

April 24, 2017

One in Five Acute MI Patients Drop Statins Within 2 Years

News Daily News

One in Five Acute MI Patients Drop Statins Within 2 Years

Michael O'Riordan

April 20, 2017

Absorb Comparable to Xience in Economic Analysis, but BVS Safety Concerns Could Alter Balance

News Daily News

Absorb Comparable to Xience in Economic Analysis, but BVS Safety Concerns Could Alter Balance

Michael O'Riordan

April 18, 2017

Scaffold Thrombosis Concerns With Absorb BVS Echoed in AIDA Trial

News Daily News

Scaffold Thrombosis Concerns With Absorb BVS Echoed in AIDA Trial

Michael O'Riordan

March 29, 2017

ABSORB III: Two-Year Results Show a Higher MACE Rate Compared With Xience

News Conference News ACC 2017

ABSORB III: Two-Year Results Show a Higher MACE Rate Compared With Xience

Michael O'Riordan

March 18, 2017

FDA Warns of Risk of Major Adverse Cardiac Events With Absorb BVS

News Conference News ACC 2017

FDA Warns of Risk of Major Adverse Cardiac Events With Absorb BVS

Michael O'Riordan

March 18, 2017

Replacing Aspirin With Low-Dose Rivaroxaban for Post-ACS Therapy Appears Safe

News Conference News ACC 2017

Replacing Aspirin With Low-Dose Rivaroxaban for Post-ACS Therapy Appears Safe

March 18, 2017

‘Hub and Spoke’ Model Promises to Improve Access to PCI for STEMI in Low- and Middle-Income Countries

News Daily News

‘Hub and Spoke’ Model Promises to Improve Access to PCI for STEMI in Low- and Middle-Income Countries

March 14, 2017

Absorb BVS: Better Technique, Better Outcomes? More Data—and More Debate

News Conference News CRT 2017

Absorb BVS: Better Technique, Better Outcomes? More Data—and More Debate

Michael O'Riordan

February 21, 2017

‘Misalignment’ Exists Between What Concerns Patients and Physicians Most After PCI

News Daily News

‘Misalignment’ Exists Between What Concerns Patients and Physicians Most After PCI

Michael O'Riordan

February 13, 2017

The COMBO Plus Dual Therapy Stent: Clinical Update and Experience

Presentation JIM 2017

The COMBO Plus Dual Therapy Stent: Clinical Update and Experience

Presenter: Gennaro Sardella

February 09, 2017

Rivaroxaban’s “Overwhelming” Efficacy for Coronary, Peripheral Disease Leads to Early Halt of COMPASS

News Daily News

Rivaroxaban’s ‘Overwhelming’ Efficacy for Coronary, Peripheral Disease Leads to Early Halt of COMPASS

February 08, 2017

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.